drugset / Trial / NCT04716725
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Phase 2
Terminated
15 enrolled
Thomas Hope
Conquer Cancer Foundation · collabGateway for Cancer Research · collabProstate Cancer Foundation · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent that may help get more detailed pictures of the tumor. This trial aims to see whether using 68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the body.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2023-09-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | — | Intravenous |